NCT02746341已完成不适用
An Observational, Prospective, Multi-center, Natural History Study of Patients With Mucopolysaccharidosis Type IIIA (MPS IIIA)
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- LYSOGENE
- 入组人数
- 23
- 试验地点
- 5
- 主要终点
- The change from baseline in cognitive function using the Bayley scales of infant and toddler development third edition
研究概览
简要总结
Evaluate the clinical progression in patients with MPS IIIA who are untreated with any investigational product and to obtain standardized assessments: neurocognitive, behavioral, sleep-wake habits and effect of MPS IIIA on the quality of life of patients and their families.
详细描述
This is a multicenter, multinational, longitudinal, observational study in children aged up to and including 9 years, who have been diagnosed with MPS IIIA. The study will detail the natural course of MPS IIIA via standardized clinical, biochemical, neurocognitive, developmental, behavioral and imaging measures. This information is anticipated to inform the design and interpretation of future interventional studies.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 0 Years 至 9 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Documented MPS IIIA diagnosis
- •Children up to and including 9 years of age
- •The patient is sufficiently able, in the opinion of the Investigator, to adhere to the study visit schedule and other protocol requirements
- •The patient's parent(s) or legal guardian(s) has signed written informed consent, according to the local regulations and after all relevant aspects of the -study have been explained and discussed
排除标准
- •The patient is participating in a clinical trial of any potential disease-modifying investigational medicinal product or taking high dose (>100 mg/kg/day) synthetic genistein (patients on low dose or naturally derived genistein can be included in this study).
- •The patient has received a hematopoietic stem cell or bone marrow transplant or gene therapy.
- •The patient has received enzyme replacement therapy in the last 6 months.
- •Homozygous or compound heterozygous for the S298P mutation or the investigator and/or trial steering committee considers the patient not to have the classical severe form of MPS IIIA.
- •Individuals with rare and unrelated serious comorbidities e.g. Down syndrome, intraventricular hemorrhage in the new-born period, or extreme low birth weight (<1500 grams).
- •Visual or hearing impairment sufficient, in the clinical judgment of the investigator, to preclude cooperation with neurodevelopmental testing. Use of hearing aids is permitted.
结局指标
主要结局
The change from baseline in cognitive function using the Bayley scales of infant and toddler development third edition
时间窗: Baseline, and every 6 months, for up to 24 months
次要结局
- Change from baseline in total cortical grey matter volume(Baseline, 12 months, 24 months)
- Change from baseline in the adaptive behavior composite standard score as measured by the Vineland Adaptive Behavior scale(Baseline and every 6 months up to 24 months)
- Sleep disturbances measured by Actigraphy(Baseline and every 3 months up to 24 months)
- Patient Quality of Life Questionnaires(Baseline and every 6 months up to 24 months)
研究者
研究点 (5)
Loading locations...
相似试验
已完成
不适用
A Study of Patients With Sanfilippo Syndrome Type A (MPS IIIA)Sanfilippo Syndrome Type ANCT01047306Shire25
进行中（未招募）
1 期
A Long-term Follow-up Study of Patients with MPS IIIA from Gene Therapy Clinical Trials Involving the Administration of ABO-102 (scAAV9.U1a.hSGSH)MPS IIIA is a devastating lysosomal storage disease, caused by a Nsulfoglucosamine sulfohydrolase gene defect. Infants with MPS IIIA appear normal at birth, but the disease is relentlessly progressive, with deterioration of social and adaptive abilities, neurocognitive decline, and premature death. Death typically occurs by end of the second or beginning of the third decade. Quite importantly, there is no treatmentcurrently available for the disease.MedDRA version: 20.1Level: PTClassification code 10056890Term: Mucopolysaccharidosis IIISystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2019-002979-34-ESAbeona Therapeutics Inc34
进行中（未招募）
1 期
A Long-term Follow-up Study of Patients with MPS IIIB from Gene Therapy Clinical Trials Involving the Administration of ABO-101 (rAAV9.CMV.hNAGLU)MPS IIIB is a devastating lysosomal storage disease, caused by a N-a-acetylglucosaminidase (NAGLU) gene defect. Infants with MPS IIIB appear normal at birth, but the disease is relentlessly progressive, with deterioration of social and adaptive abilities, neurocognitive decline, and premature death. Death typically occurs by end of the second or beginning of the third decade. Quite importantly, there is no treatment currently available for the disease.MedDRA version: 20.1Level: PTClassification code 10056890Term: Mucopolysaccharidosis IIISystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2019-002936-97-FRAbeona Therapeutics Europe SL.24
进行中（未招募）
1 期
A Long-term Follow-up Study of Patients with MPS IIIB from Gene Therapy Clinical Trials Involving the Administration of ABO-101 (rAAV9.CMV.hNAGLU)MPS IIIB is a devastating lysosomal storage disease, caused by a N-a-acetylglucosaminidase (NAGLU) gene defect. Infants with MPS IIIB appear normal at birth, but the disease is relentlessly progressive, with deterioration of social and adaptive abilities, neurocognitive decline, and premature death. Death typically occurs by end of the second or beginning of the third decade. Quite importantly, there is no treatment currently available for the disease.MedDRA version: 20.1Level: PTClassification code 10056890Term: Mucopolysaccharidosis IIISystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2019-002936-97-DEAbeona Therapeutics Europe SL.24
进行中（未招募）
1 期
A Long-term Follow-up Study of Patients with MPS IIIA from Gene Therapy Clinical Trials Involving the Administration of ABO-102 (scAAV9.U1a.hSGSH)CTIS2023-510392-66-00ltragenyx Pharmaceutical Inc.34